Chemotherapy for hormone-resistant prostate cancer: Where are we today?
Significant progress has been achieved in chemotherapy for hormone-resistant prostate cancer (HRPC) in the last five years. Although the disease was long considered to be chemoresistant, docetaxel-based regimens in particular have been shown to both palliate symptoms and prolong survival in HRPC patients. Docetaxel is now considered the best available chemotherapy for prostate cancer progressing on first-line hormonal treatment. Other cytotoxics including mitoxantrone, anthracyclines, vinorelbin and vinblastine can alleviate symptoms and improve progression-free survival in HRPC without affecting overall survival. The survival benefit from chemotherapy seen in randomized studies has been small or nonexistent. Results of a recent trial suggest that the survival benefit may have been underestimated as a result of crossover from the less active to the active arm.
Buchler
Tomas
T
Department of Oncology, University College London Hospital, London, United Kingdom.
Harland
Stephen J
SJ
Br J Cancer. 2004 Oct 18;91(8):1472-6
15381936
Oncologist. 2002;7(4):360-70
12185298
Oncology. 2005;68(1):2-9
15741753
Eur Urol. 2003 Nov;44(5):519-26
14572748
J Clin Oncol. 1996 May;14(5):1617-25
8622080
Am J Clin Oncol. 2004 Dec;27(6):550-4
15577431
N Engl J Med. 2004 Oct 7;351(15):1513-20
15470214
Prostate. 1992;20(1):43-50
1736276
Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8
15885271
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6
9815636
J Clin Oncol. 1999 Nov;17(11):3461-7
10550143
Urology. 2004 May;63(5):940-5
15134985
Int J Radiat Oncol Biol Phys. 1993 Apr 2;25(5):805-13
8478230
J Clin Oncol. 2005 May 20;23(15):3343-51
15738542
J Clin Oncol. 2001 Mar 1;19(5):1304-11
11230472
Cancer. 2006 Mar 1;106(5):1041-6
16456811
J Natl Cancer Inst. 2006 Apr 19;98(8):516-21
16622120
J Urol. 2002 Dec;168(6):2439-43
12441935
J Clin Oncol. 2005 Nov 10;23(32):8247-52
16278480
J Clin Oncol. 1999 Aug;17(8):2506-13
10561316
Eur J Cancer. 1997 Apr;33(4):566-74
9274436
Oncologist. 2005;10 Suppl 3:30-9
16368869
J Clin Oncol. 1999 Mar;17(3):958-67
10071290
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):699-703
11172951
Semin Oncol. 1999 Oct;26(5 Suppl 17):39-44
10604268
Semin Oncol. 1999 Oct;26(5 Suppl 17):28-33
10604266
N Engl J Med. 2004 Oct 7;351(15):1502-12
15470213
Eur Urol. 1997;31(1):7-10
9032527
J Clin Oncol. 1999 Oct;17(10):3160-6
10506613
J Clin Oncol. 2005 Nov 10;23(32):8253-61
16278481
J Clin Oncol. 2006 Jun 20;24(18):2828-35
16782921
Ann Oncol. 1999 Jan;10(1):33-8
10076719
Urology. 2006 Jun;67(6):1235-40
16765185
J Clin Oncol. 2001 May 1;19(9):2509-16
11331330
J Clin Oncol. 1996 Jun;14(6):1756-64
8656243
Ann Oncol. 2004 Nov;15(11):1613-21
15520061
Urology. 1992 Jun;39(6):577-82
1615614